Serum vitamin D concentration and prostate cancer risk

A nested case-control study

Jiyoung Ahn, Ulrike Peters, Demetrius Albanes, Mark P. Purdue, Christian C. Abnet, Nilanjan Chatterjee, Ronald L. Horst, Bruce W. Hollis, Wen Yi Huang, James M. Shikany, Richard B. Hayes

Research output: Contribution to journalArticle

Abstract

Background: Epidemiological studies have yielded inconsistent associations between vitamin D status and prostate cancer risk, and few studies have evaluated whether the associations vary by disease aggressiveness. We investigated the association between vitamin D status, as determined by serum 25-hydroxyvitamin D [25(OH)D] level, and risk of prostate cancer in a case-control study nested within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Methods: The study included 749 case patients with incident prostate cancer who were diagnosed 1-8 years after blood draw and 781 control subjects who were frequency matched by age at cohort entry, time since initial screening, and calendar year of cohort entry. All study participants were selected from the trial screening arm (which includes annual standardized prostate cancer screening). Conditional logistic regression was used to estimate adjusted odds ratios (ORs) with 95% confidence intervals (CIs) by quintile of season-standardized serum 25(OH)D concentration. Statistical tests were two-sided. Results: No statistically significant trend in overall prostate cancer risk was observed with increasing season-standardized serum 25(OH)D level. However, serum 25(OH)D concentrations greater than the lowest quintile (Q1) were associated with increased risk of aggressive (Gleason sum ≥7 or clinical stage III or IV) disease (in a model adjusting for matching factors, study center, and history of diabetes, ORs for Q2 vs Q1 = 1.20, 95% CI = 0.80 to 1.81, for Q3 vs Q1 =1.96, 95% CI = 1.34 to 2.87, for Q4 vs Q1 = 1.61, 95% CI = 1.09 to 2.38, and for Q5 vs Q1 = 1.37, 95% CI = 0.92 to 2.05; P trend =. 05). The rates of aggressive prostate cancer for increasing quintiles of serum 25(OH)D were 406, 479, 780, 633, and 544 per 100 000 person-years. In exploratory analyses, these associations with aggressive disease were consistent across subgroups defined by age, family history of prostate cancer, diabetes, body mass index, vigorous physical activity, calcium intake, study center, season of blood collection, and assay batch. Conclusion: The findings of this large prospective study do not support the hypothesis that vitamin D is associated with decreased risk of prostate cancer; indeed, higher circulating 25(OH)D concentrations may be associated with increased risk of aggressive disease.

Original languageEnglish (US)
Pages (from-to)796-804
Number of pages9
JournalJournal of the National Cancer Institute
Volume100
Issue number11
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Vitamin D
Case-Control Studies
Prostatic Neoplasms
Serum
Confidence Intervals
Early Detection of Cancer
Odds Ratio
Ovarian Neoplasms
Epidemiologic Studies
Colorectal Neoplasms
Lung Neoplasms
Body Mass Index
Logistic Models
Prospective Studies
Calcium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Serum vitamin D concentration and prostate cancer risk : A nested case-control study. / Ahn, Jiyoung; Peters, Ulrike; Albanes, Demetrius; Purdue, Mark P.; Abnet, Christian C.; Chatterjee, Nilanjan; Horst, Ronald L.; Hollis, Bruce W.; Huang, Wen Yi; Shikany, James M.; Hayes, Richard B.

In: Journal of the National Cancer Institute, Vol. 100, No. 11, 06.2008, p. 796-804.

Research output: Contribution to journalArticle

Ahn, J, Peters, U, Albanes, D, Purdue, MP, Abnet, CC, Chatterjee, N, Horst, RL, Hollis, BW, Huang, WY, Shikany, JM & Hayes, RB 2008, 'Serum vitamin D concentration and prostate cancer risk: A nested case-control study', Journal of the National Cancer Institute, vol. 100, no. 11, pp. 796-804. https://doi.org/10.1093/jnci/djn152
Ahn, Jiyoung ; Peters, Ulrike ; Albanes, Demetrius ; Purdue, Mark P. ; Abnet, Christian C. ; Chatterjee, Nilanjan ; Horst, Ronald L. ; Hollis, Bruce W. ; Huang, Wen Yi ; Shikany, James M. ; Hayes, Richard B. / Serum vitamin D concentration and prostate cancer risk : A nested case-control study. In: Journal of the National Cancer Institute. 2008 ; Vol. 100, No. 11. pp. 796-804.
@article{af4b10fd68934016aa2337fcbb3df678,
title = "Serum vitamin D concentration and prostate cancer risk: A nested case-control study",
abstract = "Background: Epidemiological studies have yielded inconsistent associations between vitamin D status and prostate cancer risk, and few studies have evaluated whether the associations vary by disease aggressiveness. We investigated the association between vitamin D status, as determined by serum 25-hydroxyvitamin D [25(OH)D] level, and risk of prostate cancer in a case-control study nested within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Methods: The study included 749 case patients with incident prostate cancer who were diagnosed 1-8 years after blood draw and 781 control subjects who were frequency matched by age at cohort entry, time since initial screening, and calendar year of cohort entry. All study participants were selected from the trial screening arm (which includes annual standardized prostate cancer screening). Conditional logistic regression was used to estimate adjusted odds ratios (ORs) with 95{\%} confidence intervals (CIs) by quintile of season-standardized serum 25(OH)D concentration. Statistical tests were two-sided. Results: No statistically significant trend in overall prostate cancer risk was observed with increasing season-standardized serum 25(OH)D level. However, serum 25(OH)D concentrations greater than the lowest quintile (Q1) were associated with increased risk of aggressive (Gleason sum ≥7 or clinical stage III or IV) disease (in a model adjusting for matching factors, study center, and history of diabetes, ORs for Q2 vs Q1 = 1.20, 95{\%} CI = 0.80 to 1.81, for Q3 vs Q1 =1.96, 95{\%} CI = 1.34 to 2.87, for Q4 vs Q1 = 1.61, 95{\%} CI = 1.09 to 2.38, and for Q5 vs Q1 = 1.37, 95{\%} CI = 0.92 to 2.05; P trend =. 05). The rates of aggressive prostate cancer for increasing quintiles of serum 25(OH)D were 406, 479, 780, 633, and 544 per 100 000 person-years. In exploratory analyses, these associations with aggressive disease were consistent across subgroups defined by age, family history of prostate cancer, diabetes, body mass index, vigorous physical activity, calcium intake, study center, season of blood collection, and assay batch. Conclusion: The findings of this large prospective study do not support the hypothesis that vitamin D is associated with decreased risk of prostate cancer; indeed, higher circulating 25(OH)D concentrations may be associated with increased risk of aggressive disease.",
author = "Jiyoung Ahn and Ulrike Peters and Demetrius Albanes and Purdue, {Mark P.} and Abnet, {Christian C.} and Nilanjan Chatterjee and Horst, {Ronald L.} and Hollis, {Bruce W.} and Huang, {Wen Yi} and Shikany, {James M.} and Hayes, {Richard B.}",
year = "2008",
month = "6",
doi = "10.1093/jnci/djn152",
language = "English (US)",
volume = "100",
pages = "796--804",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Serum vitamin D concentration and prostate cancer risk

T2 - A nested case-control study

AU - Ahn, Jiyoung

AU - Peters, Ulrike

AU - Albanes, Demetrius

AU - Purdue, Mark P.

AU - Abnet, Christian C.

AU - Chatterjee, Nilanjan

AU - Horst, Ronald L.

AU - Hollis, Bruce W.

AU - Huang, Wen Yi

AU - Shikany, James M.

AU - Hayes, Richard B.

PY - 2008/6

Y1 - 2008/6

N2 - Background: Epidemiological studies have yielded inconsistent associations between vitamin D status and prostate cancer risk, and few studies have evaluated whether the associations vary by disease aggressiveness. We investigated the association between vitamin D status, as determined by serum 25-hydroxyvitamin D [25(OH)D] level, and risk of prostate cancer in a case-control study nested within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Methods: The study included 749 case patients with incident prostate cancer who were diagnosed 1-8 years after blood draw and 781 control subjects who were frequency matched by age at cohort entry, time since initial screening, and calendar year of cohort entry. All study participants were selected from the trial screening arm (which includes annual standardized prostate cancer screening). Conditional logistic regression was used to estimate adjusted odds ratios (ORs) with 95% confidence intervals (CIs) by quintile of season-standardized serum 25(OH)D concentration. Statistical tests were two-sided. Results: No statistically significant trend in overall prostate cancer risk was observed with increasing season-standardized serum 25(OH)D level. However, serum 25(OH)D concentrations greater than the lowest quintile (Q1) were associated with increased risk of aggressive (Gleason sum ≥7 or clinical stage III or IV) disease (in a model adjusting for matching factors, study center, and history of diabetes, ORs for Q2 vs Q1 = 1.20, 95% CI = 0.80 to 1.81, for Q3 vs Q1 =1.96, 95% CI = 1.34 to 2.87, for Q4 vs Q1 = 1.61, 95% CI = 1.09 to 2.38, and for Q5 vs Q1 = 1.37, 95% CI = 0.92 to 2.05; P trend =. 05). The rates of aggressive prostate cancer for increasing quintiles of serum 25(OH)D were 406, 479, 780, 633, and 544 per 100 000 person-years. In exploratory analyses, these associations with aggressive disease were consistent across subgroups defined by age, family history of prostate cancer, diabetes, body mass index, vigorous physical activity, calcium intake, study center, season of blood collection, and assay batch. Conclusion: The findings of this large prospective study do not support the hypothesis that vitamin D is associated with decreased risk of prostate cancer; indeed, higher circulating 25(OH)D concentrations may be associated with increased risk of aggressive disease.

AB - Background: Epidemiological studies have yielded inconsistent associations between vitamin D status and prostate cancer risk, and few studies have evaluated whether the associations vary by disease aggressiveness. We investigated the association between vitamin D status, as determined by serum 25-hydroxyvitamin D [25(OH)D] level, and risk of prostate cancer in a case-control study nested within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Methods: The study included 749 case patients with incident prostate cancer who were diagnosed 1-8 years after blood draw and 781 control subjects who were frequency matched by age at cohort entry, time since initial screening, and calendar year of cohort entry. All study participants were selected from the trial screening arm (which includes annual standardized prostate cancer screening). Conditional logistic regression was used to estimate adjusted odds ratios (ORs) with 95% confidence intervals (CIs) by quintile of season-standardized serum 25(OH)D concentration. Statistical tests were two-sided. Results: No statistically significant trend in overall prostate cancer risk was observed with increasing season-standardized serum 25(OH)D level. However, serum 25(OH)D concentrations greater than the lowest quintile (Q1) were associated with increased risk of aggressive (Gleason sum ≥7 or clinical stage III or IV) disease (in a model adjusting for matching factors, study center, and history of diabetes, ORs for Q2 vs Q1 = 1.20, 95% CI = 0.80 to 1.81, for Q3 vs Q1 =1.96, 95% CI = 1.34 to 2.87, for Q4 vs Q1 = 1.61, 95% CI = 1.09 to 2.38, and for Q5 vs Q1 = 1.37, 95% CI = 0.92 to 2.05; P trend =. 05). The rates of aggressive prostate cancer for increasing quintiles of serum 25(OH)D were 406, 479, 780, 633, and 544 per 100 000 person-years. In exploratory analyses, these associations with aggressive disease were consistent across subgroups defined by age, family history of prostate cancer, diabetes, body mass index, vigorous physical activity, calcium intake, study center, season of blood collection, and assay batch. Conclusion: The findings of this large prospective study do not support the hypothesis that vitamin D is associated with decreased risk of prostate cancer; indeed, higher circulating 25(OH)D concentrations may be associated with increased risk of aggressive disease.

UR - http://www.scopus.com/inward/record.url?scp=44949203571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949203571&partnerID=8YFLogxK

U2 - 10.1093/jnci/djn152

DO - 10.1093/jnci/djn152

M3 - Article

VL - 100

SP - 796

EP - 804

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11

ER -